In this episode of Medtech Connect, Medtech Insight spoke to three decentralized clinical trial experts at Hogan Lovells: partner Kristin Zielinski Duggan, partner Blake Wilson and associate Stephanie Agu. We discussed the ins and outs of the draft FDA guidance document, what pieces of the guidance still might need clarification and how they expect to see the industry change as DCTs become mainstream.
Decentralized Clinical Trial Guidance Fulfills Promise, Underlies Digitization Of Healthcare
FDA Seeks Feedback On Attempt To Modernize Clinical Trials
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
